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Short communication
Major basic protein, but not
eosinophil cationic protein or
eosinophil protein X, is
related to atopy in cystic
fibrosis
Caused by mutations on chromosome 7 (1), cystic fibrosis
(CF) is an autosomal recessive disease characterized by
progressive pulmonary tissue injury due to chronic bacterial
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major basic protein.
Increased eosinophil granule proteins have been described in serum
and sputum samples of patients with cystic fibrosis (CF). It has been
assumed that eosinophil degranulation is enhanced in atopic
subjects – as in asthmatics. Since in CF no differences in eosinophil
cationic protein (ECP), eosinophil protein X (EPX), and eosinophil
peroxidase between atopic and nonatopic subjects have been
detected, we investigated whether major basic protein (MBP) is
increased in serum and sputum samples derived from atopic (n=14)
compared with nonatopic CF subjects (n=26). In CF patients, high
mean serum (sputum) levels of ECP 29.7 mg/l (2.7 mg/l), EPX 53.7 mg/l
(7.9 mg/l), and MBP 984.6 mg/l but low sputum MBP levels (57.4 mg/l)
were measured. In addition, in serum and in sputum samples, a
significant correlation between MBP and ECP (P,0.03 and P,0.0001,
respectively) or EPX (P,0.05 and P,0.0004, respectively) was
detected. By subdivision of the patients into allergic and nonallergic
subjects, significant differences were found for serum MBP values
only (mean1382.2mg/lvs770.5mg/l;P,0.0001),butnot forECPorEPX
serum levels or for eosinophil proteins in sputum. Although no
differencesbetweenatopicandnonatopicCFpatients inECPandEPX
were found, serum MBP levels were higher in patients sensitized to
inhalant allergens than in nonsensitized subjects. These results
indicate differential release of eosinophil granule proteins in
peripheral blood from eosinophils, and they also indicate that MBP
in serum likely is to be a better discriminator of atopy in CF.
1094
infection and excessive immune-mediated inflammatory
process (2). Recently, increased concentrations of
eosinophil-derived granule proteins, such as eosinophil
cationic protein (ECP), eosinophil protein X (EPX), and
eosinophil peroxidase (EPO), have been detected in both
sputum and serum samples of patients with CF (3, 4). In
addition, serum levels of eosinophil granule proteins are
significantly related to pulmonary function and disease
severity in CF (4, 5). Due to the cytotoxic potential of these
proteins, it has been assumed that the activated eosinophil,
in addition to the neutrophil granulocyte, also participates
in pulmonary tissue damage (3). However, in addition to
bacterial infection, colonization with fungi, predominately
Aspergillus fumigatus, is frequently observed in CF (6),
commonly resulting in IgE-mediated sensitization to this
fungus. Moreover, it has been demonstrated that Aspergillus
sensitization in the presence of increased total serum IgE
levels is associated with lower pulmonary function values in
children with CF (7), emphasizing the role of IgE-mediated
sensitization in CF. In contrast to bronchial asthma (8),
eosinophil activity is not enhanced in atopic compared with
nonatopic patients with CF, as shown by the lack of any
relationship between the levels of ECP, EPX, or EPO and the
atopic status of patients with CF (4). Therefore, other
mechanisms of eosinophil activation in CF compared with
bronchial asthma have been suggested (9). Despite this,
however, it appears unlikely that IgE-mediated events do not
contribute in CF to enhanced eosinophil degranulation as
measured by ECP, EPX, and EPO (4).
Since there is some evidence that eosinophil-granule
proteins are released differentially in vitro (10), we investi-
gated whether serum and sputum levels of major basic
protein (MBP) are influenced by additional IgE-mediated
sensitization in patients with CF. To have a homogeneous
cohort, all of the patients studied were in stable clinical
condition, and all of them were chronically infected/
colonized by Pseudomonas aeruginosa.
Material and methods
Patients and controls
Forty patients with CF (age: 12.5u3.47 years; 22 girls and 18
boys) were recruited. The diagnosis was confirmed by
repeated positive sweat test results and typical course of
disease. All of them were in a stable clinical condition,
meaning that none of the patients suffered from acute
pulmonary exacerbation as defined previously (4). Disease
severity was determined by means of the Shwachman–
Kulczycki score (11), which in our setting (12) was limited to
the maximum of 75 points (i.e., excluding radiography)
(Table 1). Chronic infection/colonization by P. aeruginosa
was proved by repeated sputum cultures in all patients.
In addition, in 14 patients with CF, the diagnosis of atopy
was based on increased total serum IgE proteins (above the
age-related normal values) (Table 1) and specific IgE anti-
bodies against inhalant allergens (positive results class $2)
(UniCAP, Pharmacia & Upjohn Diagnostics, Uppsala,
Sweden). Sensitization to A. fumigatus was diagnosed by
the presence of specific IgE antibodies in serum (positive
results of $class 2) and by skin prick test results in six
patients, but in none of them were the criteria of allergic
bronchopulmonary aspergillosis fulfilled (6).
Sputum preparation
Sputum samples were diluted immediately with phosphate-
buffered saline (PBS), pH 7.4, in order to avoid cell damage,
and were vortex mixed for 30 s, according to a previously
published protocol (3, 9). The mixture was centrifuged, and
the supernatant was immediately frozen at –208C until
analysis.
An aliquot of diluted sputum from each patient was used
for cell differential counts and was stained with May-
Gru¨nwald-Giemsa. It has been previously shown by trypan
blue exclusion that the viability of cells in samples was
above 65%. Moreover, the percentage of squamous cells was
less than 10%, indicating that no notable salivary contam-
ination was present (13).
Table 1. Clinical data of patients with cystic
fibrosis (n=40)
MeanuSD
Shwachman–Kulczycki score (points) 52u10.9
FVC % predicted 89.2u21.49
FEV1 % predicted 79.5u30.30
MEF50 % predicted 59.0u37.98
MEF25 % predicted 46.6u33.55
TLC % predicted 114.5u14.68
RV/TLC % predicted 165.3u61.35
Arterial PO2 (kPa) 10.5u1.62
Arterial PCO2 (kPa) 5.1u0.53
Total serum IgE (kU/l) 157u230.4
C-reactive protein (mg/l) 9.0u7.3
Blood neutrophil counts (cells/ml) 4505u1042.7
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Assays for eosinophil granule proteins and blood differentials
Eosinophils and neutrophils in peripheral blood were
determined by automated counting (Sysmex NE-5500;
Mu¨ller, Austria) with coefficients of variation of about 7%
and 4.8%, respectively (3). ECP and EPX levels were
measured by using specific and sensitive radioimmuno-
assays (Pharmacia Upjohn AB, Uppsala, Sweden). Briefly,
ECP or EPX in the samples compete with a fixed amount of
125I-labeled ECP/EPX for the binding sites of specific
antibodies (12, 14). All measurements were done in
duplicate. The interassay coefficient of variation for both
assays was below 11% (3, 6).
For determination of MBP, both serum and sputum
samples were reduced and alkylated to recover full detection
of MBP (15). MBP concentrations were determined by a two-
site immunoradiometric assay employing two monoclonal
antibodies (16). In brief, reduced and alkylated serum/
sputum samples, as well as standards, were placed in
capture antibody-coated, 96-well plates and incubated for
2 h. After washing, 125I-labeled antibody was placed in the
wells and incubated for 1 hr. Wells were washed and counted
in a gamma scintillation counter (15, 16).
Normal serum values for ECP in 87 healthy nonatopic
children (age: 10.2u4.5 years) were 9.2u3.67 mg/l (range 3.4–
16.2 mg/l) (8); for EPX in 38 healthy nonatopic subjects (age:
13.1u4.26 years), 19.4u5.87 mg/l (range 9.2–28.6 mg/l (4, 12);
and for MBP in 105 healthy controls, 454u90 mg/l (range
312–800 mg/l) (16).
Pulmonary function test
Pulmonary function tests were performed by means of a
whole-body plethysmograph (Masterlab, Jaeger, Germany).
Forced vital capacity (FVC), forced expiratory volume in 1 s
(FEV1), and maximum expiratory flow at 50% and 25% of
vital capacity (MEF50 and MEF25) were recorded as a
maximum flow-volume curve. Total lung capacity (TLC)
and residual volume (RV) were also determined. The best of
three efforts was used for analysis, according to the
American Thoracic Society standard (17). The results are
presented as percentage of predicted, according to accepted
reference values (18).
Blood gas analysis
Arterial PO2 and PCO2 values were determined in arterialized
ear-lobe capillary blood (Blood Gas Analyzer 1306 pH;
Instrumentation Laboratory, USA).
Statistical analysis
Results are presented as meanuSD unless mentioned
otherwise. The coefficient of correlation was calculated by
the Spearman ranks correlation procedure. The Mann–
Whitney U test was used for differences between the
groups. Probabilities of less than 5% were considered
significant.
Results
Clinical characteristics
Detailed demographic data of the patients are summarized
in Table 1. Subdivision into atopic (n=14) and nonatopic
(n=26) subjects demonstrated for total serum IgE levels
a significant difference (381u261.4 kU/l [range 142–884
kU/l) vs 36u16.7 kU/l [range 6–60 kU/l); P,0.0001). No
significant differences for pulmonary function variables or
other clinical parameters, such as Shwachman–Kulczycki
score and blood gas analysis, were detected.
Eosinophil counts and eosinophil granule proteins in serum
Eosinophil counts were low in most of the patients with CF
(234u117.3 eosinophils/ml; range 80–520 eosinophils/ml). In
addition, no significant differences were found between
atopic and nonatopic patients (210u114.6 vs 247u118.9
eosinophils/ml). In contrast to blood eosinophil counts,
increased ECP levels (29.7u21.01 mg/l; range: 6.4–85 mg/l),
EPX levels (53.7u31.27 mg/l; range: 15.4–145.2 mg/l), and
MBP levels (984.6u370.55 mg/l; range: 412.2–1880.3 mg/l)
were measured. In serum, MBP levels were significantly
correlated with the levels of ECP (r=0.348, P,0.03) and EPX
(r=0.321, P,0.05).
Moreover, serum MBP (Fig. 1), but not ECP and EPX
concentrations, were significantly higher in atopic
(34.8u23.94 and 65.8u26.36 mg/l, respectively) than in
nonatopic patients (27.1u19.71 and 47.1u32.20 mg/l,
respectively) with CF. However, levels of eosinophil granule
proteins and blood eosinophil counts, except serum
MBP concentrations, did not differ between Aspergillus-
sensitized and nonsensitized patients (Table 2).
Eosinophil counts and eosinophil granule proteins in sputum
In 26 out of 40 patients with CF, no eosinophils were
detected in sputum samples. In the remaining subjects,
Koller et al . Major basic protein and atopy
1096 | Allergy 54, / 1094–1099
eosinophils were 1–12% of nonsquamous cells. Despite this,
the neutrophil is the predominant cell in sputa derived from
patients with CF (85u8.7%). In addition, eosinophil
numbers in sputum samples were, on average, slightly
higher in atopic (3u3.9%) than in nonatopic patients
(0.5u1.1%; P,0.05). Sensitization to A. fumigatus, how-
ever, resulted in no statistically significant differences for
sputum eosinophil counts in atopic patients with CF
(Table 2).
Moreover, high levels of ECP (2.7u0.86 mg/l; range: 1.1–
4.45 mg/l) and of EPX (7.9u1.52 mg/l; range: 4.8–10.6 mg/l)
but only small quantities of MBP (57.4u38.10 mg/l; range:
8.0–146.9 mg/l) were detected. However, sputum concentra-
tions of MBP were closely related to those of ECP (r=0.721,
P,0.0001) and EPX (r=0.567, P,0.0004).
No differences in eosinophil granule protein levels in
sputum between atopic (ECP 2.78u0.85 mg/l and EPX
8.52u1.16 mg/l) and nonatopic patients (ECP 2.65u0.88
mg/l and EPX 7.63u1.61 mg/l) with CF were observed (Fig. 1
shows the results for MBP). In addition, in atopic subjects,
no influence on eosinophil activity by A. fumigatus
sensitization was seen (Table 2).
Discussion
The present study has demonstrated high concentrations of
ECP, EPX, and MBP in serum and of ECP and EPX in sputum
derived from patients with CF. This finding supports
previous results in patients with CF showing increased
serum and sputum ECP levels (3, 4). Moreover, we have
found that serum MBP levels, but not those for ECP and
EPX, were significantly elevated in CF patients with
sensitization to inhalant allergens, compared with nonsen-
sitized subjects. This was not seen for eosinophil counts in
peripheral blood.
The lack of blood and sputum eosinophilia does not
exclude the participation of the eosinophil in the inflam-
matory process, as recently demonstrated, for example, in
wheezing infants (19). The dissociation between eosinophil
Table 2. Influence of A. fumigatus sensitization on eosinophil counts and concentrations
of eosinophil granule proteins in atopic patients with CF
Aspergillus-positive (n=6) Aspergillus-negative (n=8) P value
Total serum IgE kU/l 324u292.0 424u247.1 NS
Blood eosinophils/ml 208u12.7 211u108.7 NS
Sputum eosinophils % 4u3.7 2u4.2 NS
Serum ECP mg/l 47.0u27.04 25.6u17.81 NS
Sputum ECP mg/l 2.6u0.74 2.9u0.93 NS
Serum EPX mg/l 71.2u36.42 61.8u17.32 NS
Sputum EPX mg/l 8.4u1.59 8.6u0.82 NS
Serum MBP mg/l 1610.9u248.08 1210.7u119.04 ,0.005
Sputum MBP mg/l 78.7u49.26 65.9u37.43 NS
Figure 1. Differences in MBP concentrations (panel A, serum; panel B, sputum) in patients with CF subdivided into allergic and nonallergic subjects.
Results are presented as individual values and as meanuSD. Significant correlation between serum MBP and total serum IgE (r=0.717, P,0.0001) was
found. Such relationship was not observed for other eosinophil granule proteins in serum or for eosinophil-derived proteins in sputum. In addition,
MBP in either serum or sputum samples was not related to levels of specific IgE antibodies.
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number in peripheral blood – which was within the normal
range in most of the patients (3) – and the serum
concentrations of eosinophil granule proteins in CF might
be explained by the fact that blood eosinophils actively
release their granule proteins during clot formation in vitro.
The enhanced degranulation may reflect the fact that
eosinophils are primed by eosinophil-active factors.
Indeed, we have previously demonstrated that isolated
blood eosinophils from patients with CF have an increased
propensity to release ECP after stimulation with serum-
treated Sephadex G-15 particles, indicating that the eosino-
phil must be primed (12). One putative principle involved in
the priming of eosinophils is interleukin (IL)-5, as has been
demonstrated in vitro and in vivo for bronchial asthma (20).
In CF, however, studies on cytokines in sputum samples
have shown that in most of the patients IL-5 could not be
detected (9). Therefore, the other priming factors involved
could be cytokines such as IL-3 and IL-8, since both were
found to be increased in sputum samples from patients with
CF, and they were markedly correlated with eosinophil
activity (9). The lack of sputum eosinophilia in most of the
patients might be due to the fact that after total degranula-
tion the eosinophil cannot be identified by the usual
staining procedure. However, the participation of activated
eosinophils in the inflammatory process in the CF lung
appears to be substantiated by the presence of very high
sputum concentrations of ECP and EPX – higher than those
needed for tissue injury in vitro – as shown by our group and
others (3, 9, 21).
Surprisingly, the levels of MBP in sputum samples from
patients with CF were low despite increased ECP and EPX
values. It has been shown that patients with bronchial
asthma had similar sputum ECP levels to those of subjects
with CF (9, 22). In addition, sputum MBP concentrations
higher than 100 mg/l have been described in bronchial
asthma (23), whereas 32 of our patients with CF had values
less than 100 mg/l. Moreover, these sputum concentrations
of MPB were substantially lower than those in serum (range
412.2–1.880.3 mg/l; for comparison, in asthmatics, a mean
concentration of 384 mg/l has been described [24]). The
reason for this phenomenon might be either that MBP is
degraded by the presence of proteolytic enzymes in the
sputum of patients with CF, or that eosinophil granule
proteins are released differentially in serum and sputum (10).
Since the recovery rate for ECP and EPX is is 85–107% in
sputum samples derived from patients with CF, it appears
unlikely that among these proteins only MBP should be
degraded. Nonetheless, there is some evidence from this
study that eosinophil proteins are released differentially
from the granules. This phenomenon is probably due to the
fact that MBP is localized to the crystalline core of the
eosinophil-specific granules whereas ECP, EPX, and eosi-
nophil peroxidase are present within the amorphous granule
matrix (25). A difference in solubilization rates between
matrix and core may possibly account for the differential
release of these proteins.
It has been demonstrated that sensitization to inhalant
allergens, especially A. fumigatus, is associated with lower
pulmonary function values in patients with CF (7), and the
observation may be due to the presence of MBP, which is
detected in higher serum concentrations in atopic than in
nonatopic patients with CF, and in Aspergillus-sensitized
than in nonsensitized subjects. Thus, our findings of
increased serum MBP levels suggest that inhalant allergy
contributes to enhanced eosinophil activity in CF, as
observed in childhood asthma (8).
In conclusion, in serum samples obtained from patients
with CF, high levels of MBP can be measured. In addition,
blood eosinophils of allergic subjects with CF released
higher amounts of MBP than those of nonallergic subjects.
This was not observed for ECP, EPX, and EPO (4). Our
results may also indicate that eosinophil granule proteins
are released differentially in patients with CF. The mechan-
ism of priming of the eosinophils is still unknown and needs
further investigation. Nonetheless, despite low MBP con-
centrations in sputum, very high ECP and EPX levels were
measured, concentrations higher than those needed for
tissue injury in vitro.
Acknowledgments We thank Gerald J. Gleich and Diane
Squillace (Department of Immunology, Mayo Clinic, Rochester,
Minnesota, USA) for their skillful determinations of MBP in
serum and in sputum samples.
References
1. Riordan JR, Rommens JM, Kerem B, et al.
Identification of the cystic fibrosis gene:
cloning and characterization of
complementary DNA. Science
1989;245:1066–1073 (Erratum, 1437).
2. Berger M. Inflammation in the lung of cystic
fibrosis. In: Gershwin E, editor. Clinical
reviews in allergy. Vol. 9. New York: Karger,
1987:119–142.
3. Koller DY, Go¨tz M, Eichler I, Urbanek R.
Eosinophilic activation in cystic fibrosis.
Thorax 1994;49:496–499.
Koller et al . Major basic protein and atopy
1098 | Allergy 54, / 1094–1099
4. Koller DY, Nilsson M, Enander I, Venge P,
Eichler I. Serum eosinophil cationic protein,
eosinophil protein X and eosinophil
peroxidase in relation to pulmonary function
in cystic fibrosis. Clin Exp Allergy
1998;28:241–248.
5. Koller DY, Go¨tz M, Wojnarowski C, Eichler I.
Relationship between disease severity and
inflammatory markers in cystic fibrosis. Arch
Dis Child 1996;75:498–501.
6. Laufer P, Fink JN, Bruns WT, et al. Allergic
bronchopulmonary aspergillosis in cystic
fibrosis. J Allergy Clin Immunol 1984;73:44–
48.
7. Wojnarowski C, Eichler I, Gartner C, et al.
Sensitization to Aspergillus fumigatus and
lung function in children with cystic fibrosis.
Am J Respir Crit Care Med 1997;155:1902–
1907.
8. Koller DY, Herouy Y, Go¨tz M, Hagel E,
Urbanek R, Eichler I. Clinical value of
monitoring eosinophil activity in asthma.
Arch Dis Child 1995;73:413–417.
9. Koller DY, Nething I, Otto J, Urbanek R,
Eichler I. Cytokine concentrations in sputum
from patients with cystic fibrosis and their
relation to eosinophil activity. Am J Respir
Crit Care Med 1997;155:1050–1054.
10. Tomassini M, Tsicopoulos A, Tai PC, et al.
Release of granule proteins by eosinophils
from allergic and nonallergic patients with
eosinophilia on immunoglobulin-dependent
activation. J Allergy Clin Immunol
1991;88:365–375.
11. Shwachman H, Kulczycki L. Long-term study
of 105 patients with cystic fibrosis. Am J Dis
Child 1958;96:6–15.
12. Koller DY, Urbanek R, Go¨tz M. Increased
degranulation of eosinophil and neutrophil
granulocytes in cystic fibrosis. Am J Respir
Crit Care Med 1995;152:629–633.
13. Pizzichini E, Pizzichini M, Efthimiadis A, et
al. Indices of airway inflammation in induced
sputum: reproducibility and validity of cell
and fluid phase measurements. Am J Respir
Crit Care Med 1996;154:308–317.
14. Peterson CGB, Enander I, Nystrand J,
Anderson AS, Nilsson L, Venge P.
Radioimmunoassay of human eosinophil
cationic protein (ECP) by an improved
method. Establishment of normal levels in
serum and turnover in vivo. Clin Exp Allergy
1991;21:561–567.
15. Wassom DL, Loegering DA, Solley GO, et al.
Elevated serum levels of the eosinophil
granule major basic protein in patients with
eosinophilia. J Clin Invest 1981;67:651–661.
16. Wagner JM, Bartemes K, Vernof KK, et al.
Analysis of pregnancy-associated major basic
protein levels throughout gestation. Placenta
1993;14:671–681.
17. American Thoracic Society. Standardization
of spirometry – 1987 update. Am Rev Respir
Dis 1987;2:1285–1298.
18. Zapletal A, Samanek M, Paul T. Lung
function in children and adolescents.
Methods, reference values. Prog Respir Res
1987;22:113–218.
19. Koller DY, Wojnarowski C, Herkner KR, et al.
High levels of eosinophil cationic protein in
wheezing infants predict the development of
asthma. J Allergy Clin Immunol
1997;99:752–756.
20. Schweizer RC, Welmers BA, Raaijmakers JA,
Zanen P, Lammers JW, Koendermen L.
RANTES- and IL-8-induced responses in
normal human eosinophils: effects of priming
with interleukin-5. Blood 1994;83:3697–
3704.
21. Reimert CM, Giwercman B, Hoiby N,
Kharazmi A. Eosinophil cationic protein in
sputum from cystic fibrosis patients with
Pseudomonas aeruginosa infections. Lancet
1994;344:1504–1505.
22. Virchow JC, Ho¨lscher U, Virchow C. Sputum
ECP levels correlate with parameters of
airflow obstruction. Am Rev Respir Dis
1992;146:604–606.
23. Por PJ, Ackerman SJ, Gleich GJ. Charcot-
Leyden crystal protein and eosinophil major
basic protein in sputum of patients with
respiratory diseases. Am Rev Respir Dis
1984;130:1072–1077.
24. Abu-Ghazaleh RI, Dunette SL, Loegering DA,
et al. Eosinophil granule proteins in
peripheral blood granulocytes. J Leukoc Biol
1992;52:611–618.
25. Gleich GJ, Leiferman KM. Eosinophils and
hypersensitivity diseases. In: Reed CE, editor.
Proceedings of the XII International
Congress of Allergology and Clinical
Immunology. St Louis, MO: CV Mosby,
1986:124–131.
Koller et al . Major basic protein and atopy
Allergy 54, / 1094–1099 | 1099
